Premium
INVOLVEMENT OF PROLYLCARBOXYPEPTIDASE IN THE EFFECT OF RUTAECARPINE ON THE REGRESSION OF MESENTERIC ARTERY HYPERTROPHY IN RENOVASCULAR HYPERTENSIVE RATS
Author(s) -
Qin XuPing,
Zeng SiYu,
Tian HaiHong,
Deng ShuiXiu,
Ren JunFang,
Zheng YuanBin,
Li Dai,
Li YuanJian,
Liao DuanFang,
Chen ShiYou
Publication year - 2009
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2008.05079.x
Subject(s) - rutaecarpine , medicine , renovascular hypertension , endocrinology , mesenteric arteries , losartan , blood pressure , muscle hypertrophy , artery , vascular smooth muscle , lumen (anatomy) , angiotensin ii , pharmacology , smooth muscle
SUMMARY1 Previous studies indicate that rutaecarpine blocks increases in blood pressure and inhibits vascular hypertrophy in experimentally hypertensive rats. The aim of the present study was to determine whether the effects of rutaecarpine are related to activation of prolylcarboxypeptidase (PRCP). 2 Renovascular hypertensive rats (Goldblatt two‐kidney, one‐clip (2K1C)) were developed using male Sprague‐Dawley rats. Chronic treatment with rutaecarpine (10 or 40 mg/kg per day) or losartan (20 mg/kg per day) for 4 weeks to the hypertensive rats caused a sustained dose‐dependent attenuation of increases in blood pressure, increased lumen diameter and decreased media thickness, which was accompanied by a similar reduction in the media cross‐sectional area : lumen area ratio in mesenteric arteries compared with untreated hypertensive rats. 3 Angiotensin (Ang) II expression was significantly increased in mesenteric arteries of hypertensive rats compared with sham‐operated rats. No significant differences in plasma AngII levels were observed between untreated hypertensive and sham‐operated rats. Hypertensive rats treated with high‐dose rutaecarpine had significantly decreased Ang II levels in both the plasma and mesenteric arteries. 4 Expression of PRCP protein or kallikrein mRNA was significantly inhibited in the right kidneys and mesenteric arteries of hypertensive rats. However, expression of PRCP protein and kallikrein mRNA was significantly increased after treatment with rutaecarpine or losartan (20 mg/kg per day). 5 The data suggest that the repression of increases in systolic blood pressure and reversal of mesenteric artery remodelling by rutaecarpine may be related to increased expression of PRCP in the circulation and small arteries in 2K1C hypertensive rats.